Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002507 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002507 is a Phase 3 study that has completed, run by Yale University.
The verdict
NCT00002507, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treating patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus either mitomycin or porfiromycin in treating patients with head and neck cancer.
Interventions
- RADIATION radiation therapy
- RADIATION brachytherapy
- DRUG mitomycin C
- DRUG porfiromycin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-11 |
| Est. Completion | 2002-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002507
The ClinicalTrials.gov registry entry for NCT00002507 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which radiation therapy is the first listed.
NCT00002507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002507 about?
NCT00002507 is a clinical study titled "Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treatin...
What is the current status of trial NCT00002507?
This trial is currently completed. It is a Phase 3 study. The study started on 1992-11. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00002507?
The interventions under investigation include: radiation therapy (RADIATION), brachytherapy (RADIATION), mitomycin C (DRUG), porfiromycin (DRUG).
Who is sponsoring clinical trial NCT00002507?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.